Abstract
Abstract 19052: Interferon B1A-Induced Dilated Cardiomyopathy
Circulation (New York, N.Y.), Vol.148(Suppl_1), pp.A19052-A19052
11/07/2023
DOI: 10.1161/circ.148.suppl_1.19052
Abstract
Abstract only
Introduction:
Congestive heart failure is a leading causes of morbidity and mortality. Interferon therapy is a rare cause of dilated cardiomyopathy (DCM) and Heart Failure with Reduced Ejection Fraction (HFrEF). Specifically, interferon Alpha has been associated with cardiotoxicity. Here we describe a case of interferon B1A - induced HFrEF and DCM in a patient who took subcutaneous Interferon B1A for 11 years before developing clinical signs of heart failure. To our knowledge, only four other cases have been reported.
Case Description:
A 70-year-old man with a history of multiple sclerosis managed with Interferon B1A presented with shortness of breath, orthopnea, and lower extremity edema for 10 days. Physical examination revealed jugular venous distension and pitting edema. Brain natriuretic peptide (BNP) was 1580 pg/mL, troponin was 49 ng/L. Lipid panel, complete blood count, complete metabolic panel, Hemoglobin A1c, and thyroid stimulating hormone were within normal limits. Urine drug screen was negative. Chest X-ray revealed pulmonary vascular congestion and small pleural effusions bilaterally. A Transthoracic echocardiogram revealed mild aortic root dilatation (4.1cm), significant four-chamber dilatation, severely reduced left ventricular (LV) systolic function with an estimated ejection fraction of 20%, diastolic LV dysfunction, and moderately reduced systolic RV function, consistent with HFrEF and DCM (LVIDD 6.1cm). Coronary angiography showed normal coronary anatomy. The patient was started on guideline-directed medical therapy for HFrEF. Close follow-up was arranged to track improvement in systolic function after cessation of interferon b1a and consideration for Cardiac MRI and possible RV biopsy to evaluate for other causes of cardiomyopathy.
Discussion/Conclusions:
Due to the patient’s negative ischemic workup and absence of risk factors for cardiovascular disease, we strongly suspect that the patient’s cardiomyopathy was due to interferon B1A. With only 4 other cases of interferon B1A-induced DCM reported, it is a rare cause of medication-induced DCM. Interferon B1A should be considered a potential risk factor for developing heart failure, especially in high-risk patients.
Details
- Title: Subtitle
- Abstract 19052: Interferon B1A-Induced Dilated Cardiomyopathy
- Creators
- Michael DiCaro - University of Nevada, Las VegasScott Turnbull - University of Nevada, Las VegasAla Abdallah - University of Nevada, Las VegasKaChon Lei - University of Nevada, Las VegasChowdhury H Ahsan - Univ Med Cntr, Las Vegas, NV
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.148(Suppl_1), pp.A19052-A19052
- DOI
- 10.1161/circ.148.suppl_1.19052
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Language
- English
- Date published
- 11/07/2023
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984845466102771
Metrics
1 Record Views